Study wrapper · #869
Pharmacologic Treatment for Obstructive Sleep Apnea in Older Adults.
Jaganathan N, Brower D, Healy WJ Drugs & aging. 2026.
DOI: 10.1007/s40266-026-01311-yPubMed: 42435144
Editor's note
A narrative review of pharmacologic options for obstructive sleep apnea in older adults, within which GLP-1 receptor agonists and specifically tirzepatide are highlighted for improving hypoxic burden, apnea-hypopnea index, and sleep outcomes by reducing upper-airway adiposity. Tirzepatide is one of several agents surveyed rather than the paper's sole focus, and review-level summaries inherit the limits of the trials they cite. Useful orientation on an emerging tirzepatide indication, with modest standalone signal.
Plain-language abstract
This review of medication options for sleep apnea in older adults notes that GLP-1 drugs, and tirzepatide in particular, improved airway and sleep measures by reducing fat around the upper airway.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Weak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Tissue & celln=——2026
Mixed
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Obesity pillarsn=——2026